ImmunityBio is a company that works on medicines to help people fight diseases. Some very important and rich people, called whales, have been buying and selling parts of the company called options. They think the price of ImmunityBio's medicine will change in the next few months. The whales are trying to guess if the company will do well or not. Read from source...

1. The title is misleading and sensationalist, implying that the whales are doing something special or important with IBRX, while in reality they are just making options trades like any other investor.
2. The article lacks credible sources and factual evidence to support its claims about the whales' intentions and knowledge of future events related to IBRX.
3. The overall sentiment analysis is based on a small sample size of 19 uncommon options trades, which is not representative of the entire market or even the institutional investors who trade IBRX options.
4. The expected price movements are based on arbitrary and subjective criteria, such as volume and open interest, without considering other relevant factors such as earnings, fundamentals, valuation, etc.

Analysis: The article discusses the recent unusual options trading activities for IBRX by whales or large investors. It also provides some details on the volume and open interest in the contracts. The overall sentiment of these big-money traders is split between bullish (31%) and bearish (63%). This indicates a mixed view among the whales regarding the future direction of IBRX's stock price. However, the fact that they are making such large bets with options suggests that they expect some significant movement in the share price soon. Therefore, the article's sentiment can be classified as neutral to slightly positive, as it does not clearly endorse or reject either bullish or bearish outlook for IBRX.

1. Buy IBRX call options with a strike price of $5.00 expiring on November 26, 2021. This option has a high potential for gain as it is significantly undervalued compared to the current market price of IBRX ($3.79). The risk-reward ratio is favorable, with a potential return of over 45% if IBRX reaches $6.00 by expiration date. Additionally, this option has high liquidity and open interest, indicating strong interest from large investors who may be expecting a price increase in the near future.

2. Sell IBRX put options with a strike price of $3.50 expiring on November 26, 2021. This option has a low risk profile as it is slightly out-of-the-money and provides downside protection if IBRX drops below the current market price. The potential return is limited to the premium received from selling the option, which is approximately 4% of the current market value of IBRX. This strategy can be used to generate income or hedge against potential losses in other positions.

3. Establish a long position in IBRX shares by purchasing them on the open market. This investment recommendation is based on the strong institutional and insider buying activity observed in recent weeks, as well as the positive clinical trial results reported by ImmunityBio. The current price of IBRX ($3.79) represents a significant discount to its 52-week high of $14.80, offering an attractive entry point for investors who believe in the long-term potential of the company and its products.

4. Monitor the news and developments related to ImmunityBio and IBRX, as well as the broader biotechnology sector. This is important to stay informed about any upcoming catalysts that may impact the stock price, such as regulatory approvals, clinical trial updates, or partnership announcements. Additionally, keep an eye on the overall market sentiment and trends in the biotechnology industry, which may influence the performance of IBRX and other similar investments.